# Idarubicin Overcomes MDR1 Induced Chemoresistance With Higher Induction Remission Rate and Quality Than Daunorubicin in Acute Myeloid Leukemia Patients

> **NCT01889407** · — · UNKNOWN · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 94 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Idarubicin

## Key facts

- **NCT ID:** NCT01889407
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-08
- **Primary completion:** 2016-07
- **Final completion:** 2016-07
- **Target enrollment:** 94 (ESTIMATED)
- **Last updated:** 2015-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01889407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01889407, "Idarubicin Overcomes MDR1 Induced Chemoresistance With Higher Induction Remission Rate and Quality Than Daunorubicin in Acute Myeloid Leukemia Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01889407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*